![Josefin-Beate Holz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Josefin-Beate Holz
Former positions of Josefin-Beate Holz
Companies | Position | Start | End |
---|---|---|---|
ABLYNX | Chief Tech/Sci/R&D Officer | 26/05/2009 | 29/06/2013 |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Corporate Officer/Principal | - | - |
Training of Josefin-Beate Holz
Philipps University of Marburg | Doctorate Degree |
Statistics
International
Germany | 3 |
Belgium | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
- Stock Market
- Insiders
- Josefin-Beate Holz
- Experience